The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nabpaclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer.
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Boston Biomedical; Celgene; Genentech/Roche; Guardant Health; Ipsen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Ipsen
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)
 
Andrew M. Lowy
Honoraria - Celgene
Consulting or Advisory Role - Halozyme; Merck
Research Funding - Mitsubishi Tanabe Pharma; Syros Pharmaceuticals
Expert Testimony - Merck
Travel, Accommodations, Expenses - Pfizer
 
Peter J. O'Dwyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Genentech
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics
 
Gayle S. Jameson
Honoraria - Celgene
Speakers' Bureau - Celgene
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Biogen (I); Fujifilm; Genzyme (I); Ipsen; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genzyme (I); Ipsen; Novartis (I); Taiho Pharmaceutical; Teva (I)
Research Funding - Ambry Genetics (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
 
Hitendra Patel
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Clare Massey
Employment - BerGenBio
 
Julia Schoelermann
Employment - BerGenBio
 
James Lorens
Employment - BerGenBio
 
Farjana Fattah
No Relationships to Disclose
 
Kimberli Crane
No Relationships to Disclose
 
Erin Fenske Williams
Consulting or Advisory Role - Lilly
Travel, Accommodations, Expenses - Lilly
 
Jatan Clark
No Relationships to Disclose
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; Capella Therapeutics; Cell Therapeutics; CerRx; McKesson; Medtronic; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - 2X Oncology; 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Aduro Biotech; Aeglea Biotherapeutics; Agenus; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; Araxes Pharma; ARIAD; ARMO BioSciences; Arvinas; Athenex; Bellicum Pharmaceuticals; BiolineRx; Biospecifics Technologies; Boston Biomedical; CanBas; Cancer Prevention Pharmaceuticals; Cerulean Pharma; Codiak Biosciences; CORRONA; CV6 Therapeutics; CytomX Therapeutics; Decoy Biosystems; Defined Health; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; FibroGen; Five Prime Therapeutics; FORMA Therapeutics; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Globe Life Science; Histogen; Horizon Discovery; Horizon Pharma; HUYA Bioscience International; Imaging Endpoints; Immodulon Therapeutics; Immunophotonics; Innate Pharma; Innokeys; Insys Therapeutics; Intezyne Technologies; Ipsen; Jounce Therapeutics; Kalos Therapeutics; Kelun; Kura Oncology; L.E.A.F. Pharmaceuticals; Lilly; Lixte Biotechnology; Medical Prognosis Institute; miRNA Therapeutics; Novita Pharmaceuticals; Novocure; Nucana; Oncology Venture; Oncolyze; OSI Pharmaceuticals; Pharmamab; Phosplatin Therapeutics; RadImmune; Reflexion Medical; RenovoRx; Riptide Bioscience; Samumed; Samus Therapeutics; SciClone; Senhwa Biosciences; SOBI; SOTIO; Strategia Therapeutics; Sumitomo Dainippon; Sun Biopharma; Synergene; Systems Imagination; TargaGenix; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trans Med; Trovagene; Veana Therapeutics; Verily; Vertex; Viamet Pharmaceuticals; Vicus Therapeutics
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - Genentech/Roche
 
Rolf A. Brekken
No Relationships to Disclose